| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERV.11.77 |
| P698 | PubMed publication ID | 21692703 |
| P2093 | author name string | Janet Plate | |
| P2860 | cites work | Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer | Q24622837 |
| Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study | Q24652592 | ||
| Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma | Q47221022 | ||
| Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. | Q47745236 | ||
| Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. | Q51528727 | ||
| Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. | Q51803685 | ||
| Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. | Q52020454 | ||
| PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. | Q53255741 | ||
| Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation | Q56815463 | ||
| Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma | Q56899396 | ||
| Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity | Q59074350 | ||
| Mesothelin targeted cancer immunotherapy | Q24656242 | ||
| Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays | Q28185685 | ||
| Mesothelin: a new target for immunotherapy | Q28268571 | ||
| Tumor angiogenesis | Q29614938 | ||
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 | ||
| Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse | Q29620396 | ||
| Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study | Q33383758 | ||
| Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation | Q33887648 | ||
| Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 | Q34049250 | ||
| Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). | Q34049260 | ||
| Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras | Q34115737 | ||
| Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy | Q34149569 | ||
| Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells | Q34304405 | ||
| Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. | Q34492778 | ||
| Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. | Q34508125 | ||
| Focus on pancreas cancer | Q34768641 | ||
| Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. | Q34875973 | ||
| A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation | Q34904065 | ||
| The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research | Q35000726 | ||
| Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer | Q35810104 | ||
| Development of the PANVAC-VF vaccine for pancreatic cancer | Q36383786 | ||
| Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients | Q36399737 | ||
| Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer | Q36412657 | ||
| PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma | Q36764939 | ||
| Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. | Q36787548 | ||
| Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer | Q36900726 | ||
| Current immunotherapeutic strategies in pancreatic cancer | Q37005912 | ||
| MUC1 immunotherapy. | Q37773241 | ||
| Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. | Q39850362 | ||
| Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer | Q39981172 | ||
| Effect of Cyclophosphamide on Immunological Control Mechanisms | Q40113295 | ||
| PankoMab: a potent new generation anti-tumour MUC1 antibody | Q40314964 | ||
| MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines | Q40433320 | ||
| A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth | Q40692331 | ||
| Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer | Q41705602 | ||
| Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer | Q43041616 | ||
| Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer | Q43237571 | ||
| Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy | Q45003964 | ||
| Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer | Q45205147 | ||
| Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial | Q46852439 | ||
| P433 | issue | 6 | |
| P921 | main subject | pancreatic cancer | Q212961 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 825-836 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | Expert Review of Vaccines | Q15756339 |
| P1476 | title | Clinical trials of vaccines for immunotherapy in pancreatic cancer | |
| P478 | volume | 10 |
| Q28395823 | Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors |
| Q34353635 | Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer |
| Q40161224 | Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine |
| Q38068234 | Recent progress in canine tumor vaccination: potential applications for human tumor vaccines |
| Q37606102 | Role of immune cells in pancreatic cancer from bench to clinical application: An updated review |
| Q40166620 | Safety and efficacy study of lung cancer stem cell vaccine |
| Q37710295 | The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. |
| Q57594208 | Vaccines in clinical trials: cancer |
Search more.